Myb-like, SWIRM, and MPN domains 1 (MYSM1) deficiency: Genotoxic stress-associated bone marrow failure and developmental aberrations
Ehsan Bahrami 1, Maximilian Witzel 1, Tomas Racek 1, Jacek Puchałka 1, Sebastian Hollizeck 1, Naschla Greif-Kohistani 1, Daniel Kotlarz 1, Hans-Peter Horny 2, Regina Feederle 3, Heinrich Schmidt 1, Roya Sherkat 4, Doris Steinemann 5, Gudrun Göhring 5, Brigitte Schlegelbeger 5, Michael H Albert 1, Waleed Al-Herz 6, Christoph Klein 7
Affiliations
Affiliations
- Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität, Munich, Germany.
- Institute for Pathology, Faculty of Medicine, Ludwig-Maximilians-Universität, Munich, Germany.
- Helmholtz Zentrum München, German Research Center for Environmental Health, Core Facility Monoclonal Antibody Development, Munich, Germany.
- Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
- Institute of Human Genetics, Hannover Medical School, Hannover, Germany.
- Department of Pediatrics, Faculty of Medicine, Kuwait University, and Department of Pediatrics, Al-Sabah Hospital, Kuwait City, Kuwait.
- Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität, Munich, Germany. Electronic address: christoph.klein@med.uni-muenchen.de.
Abstract
Background: Myb-like, SWIRM, and MPN domains 1 (MYSM1) is a transcriptional regulator mediating histone deubiquitination. Its role in human immunity and hematopoiesis is poorly understood.
Objectives: We sought to investigate the clinical, cellular, and molecular features in 2 siblings presenting with progressive bone marrow failure (BMF), immunodeficiency, and developmental aberrations.
Methods: We performed genome-wide homozygosity mapping, whole-exome and Sanger sequencing, immunophenotyping studies, and analysis of genotoxic stress responses. p38 activation, reactive oxygen species levels, rate of apoptosis and clonogenic survival, and growth in immune and nonimmune cells were assessed. The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) was monitored.
Results: We report 2 patients with progressive BMF associated with myelodysplastic features, immunodeficiency affecting B cells and neutrophil granulocytes, and complex developmental aberrations, including mild skeletal anomalies, neurocognitive developmental delay, and cataracts. Whole-exome sequencing revealed a homozygous premature stop codon mutation in the gene encoding MYSM1. MYSM1-deficient cells are characterized by increased sensitivity to genotoxic stress associated with sustained induction of phosphorylated p38 protein, increased reactive oxygen species production, and decreased survival following UV light-induced DNA damage. Both patients were successfully treated with allogeneic HSCT with sustained reconstitution of hematopoietic defects.
Conclusions: Here we show that MYSM1 deficiency is associated with developmental aberrations, progressive BMF with myelodysplastic features, and increased susceptibility to genotoxic stress. HSCT represents a curative therapy for patients with MYSM1 deficiency.
Keywords: Immunodeficiency; hematopoiesis; rare disease; stem cells; transplantation.
Similar articles
Le Guen T, Touzot F, André-Schmutz I, Lagresle-Peyrou C, France B, Kermasson L, Lambert N, Picard C, Nitschke P, Carpentier W, Bole-Feysot C, Lim A, Cavazzana M, Callebaut I, Soulier J, Jabado N, Fischer A, de Villartay JP, Revy P.J Allergy Clin Immunol. 2015 Dec;136(6):1619-1626.e5. doi: 10.1016/j.jaci.2015.06.008. Epub 2015 Jul 26.PMID: 26220525
Barhoom D, Mohseni R, Behfar M, Hamidieh AA.Pediatr Transplant. 2021 Nov;25(7):e14089. doi: 10.1111/petr.14089. Epub 2021 Jul 24.PMID: 34302415
Mysm1 expression in the bone marrow niche is not essential for hematopoietic maintenance.
Petrov JC, Nijnik A.Exp Hematol. 2017 Mar;47:76-82.e3. doi: 10.1016/j.exphem.2016.10.013. Epub 2016 Nov 8.PMID: 27833034
Deubiquitinase MYSM1 in the Hematopoietic System and beyond: A Current Review.
Fiore A, Liang Y, Lin YH, Tung J, Wang H, Langlais D, Nijnik A.Int J Mol Sci. 2020 Apr 24;21(8):3007. doi: 10.3390/ijms21083007.PMID: 32344625 Free PMC article. Review.
Or R, Aker M, Shapira MY, Resnick I, Bitan M, Samuel S, Slavin S.Springer Semin Immunopathol. 2004 Nov;26(1-2):133-42. doi: 10.1007/s00281-004-0169-z. Epub 2004 Sep 30.PMID: 15549305 Review.
Cited by
Autoimmune Neutropenia and Immune-Dysregulation in a Patient Carrying a TINF2 Variant.
Chianucci B, Grossi A, Dell'Orso G, Palmisani E, Lanciotti M, Terranova P, Pierri F, Lupia M, Arcuri L, Laurino M, Ceccherini I, Beier F, Dufour C, Fioredda F, Miano M.Int J Mol Sci. 2022 Nov 22;23(23):14535. doi: 10.3390/ijms232314535.PMID: 36498862 Free PMC article.
Zhang H, Liu S, Qin Q, Xu Z, Qu Y, Wang Y, Wang J, Du Z, Yuan S, Hong S, Chang Z, He W, Yan X, Lang Y, Tang R, Wang Y, Zhu L, Jiang X.Adv Sci (Weinh). 2022 Nov 22;10(1):e2204463. doi: 10.1002/advs.202204463. Online ahead of print.PMID: 36414403 Free PMC article.
Lessons From Pediatric MDS: Approaches to Germline Predisposition to Hematologic Malignancies.
Avagyan S, Shimamura A.Front Oncol. 2022 Mar 9;12:813149. doi: 10.3389/fonc.2022.813149. eCollection 2022.PMID: 35356204 Free PMC article. Review.
Chen X, Wang W, Li Y, Huo Y, Zhang H, Feng F, Xi W, Zhang T, Gao J, Yang F, Chen S, Yang A, Wang T.J Exp Clin Cancer Res. 2021 Oct 27;40(1):341. doi: 10.1186/s13046-021-02106-2.PMID: 34706761 Free PMC article.
Mantravadi V, Bednarski JJ, Ritter MA, Gu H, Kolicheski AL, Horner C, Cooper MA, Kitcharoensakkul M.Front Immunol. 2021 Sep 3;12:734096. doi: 10.3389/fimmu.2021.734096. eCollection 2021.PMID: 34539671 Free PMC article.